HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed.

AbstractBACKGROUND:
This is a quantitative review of existing studies of transdermal selegiline for major depressive disorder.
METHODS:
Data for dichotomous outcomes were extracted from the five 6-8 week studies of transdermal selegiline. Number needed to treat (NNT) vs. placebo was calculated for response and remission using standard definitions. Number needed to harm (NNH) vs. placebo for commonly encountered adverse events (AEs), AEs associated with sexual function, incidence of weight gain ≥5% from baseline, and discontinuation due to an AE, were also calculated. Data was pooled as appropriate and likelihood to be helped or harmed (LHH) ratios contrasting remission with selected tolerability outcomes were determined.
RESULTS:
When pooling together the two pivotal trials as identified in product labeling, NNT for response was 11 (95% CI 6-109) and for remission, 9 (95% CI 6-28). Pooling all trials, NNH for application site reaction was 7 (95% CI 6-10) and for insomnia, 19 (95% CI 12-41). There were no clinically relevant differences from placebo regarding weight gain or impairment in sexual functioning. NNH for discontinuation due to an AE was 32 (95% CI 19-132). LHH for remission vs. discontinuation from treatment due to an AE was 3.6.
LIMITATIONS:
The studies included were not identical in design. The studies were registrational in nature and thus not necessarily generalizable.
CONCLUSIONS:
NNT for transdermal selegiline for efficacy is similar to that for other antidepressant regimens for which similar analyses have been published. There appear to be no clinically relevant effects of selegiline on weight or sexual functioning.
AuthorsLeslie Citrome, Joseph F Goldberg, Kimberly Blanchard Portland
JournalJournal of affective disorders (J Affect Disord) Vol. 151 Issue 2 Pg. 409-417 (Nov 2013) ISSN: 1573-2517 [Electronic] Netherlands
PMID23890583 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright© 2013 Elsevier B.V. All rights reserved.
Chemical References
  • Antidepressive Agents
  • Selegiline
Topics
  • Administration, Cutaneous
  • Antidepressive Agents (administration & dosage)
  • Biomedical Research
  • Depressive Disorder, Major (drug therapy)
  • Humans
  • Randomized Controlled Trials as Topic
  • Research Design
  • Selegiline (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: